EMA seeks to issue guidance on liver damage from Novartis’ gene therapy
(Reuters) -The European Medicines Agency (EMA) said on Friday it plans to issue advice for physicians using Novartis AG’s Zolgensma, calling on them to monitor patients for any liver injury after treatment. The statement follows two deaths due to liver failure after treatment with the gene therapy against spinal muscular atrophy, reported by Novartis in …
EMA seeks to issue guidance on liver damage from Novartis’ gene therapy Read More »










